Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving Average - Here's What Happened

Key Points

• Price action: Seres Therapeutics' shares crossed below its 50‑day moving average, trading as low as $8.27 and last at $8.32 (50‑day MA $9.70; 200‑day MA $14.49), down about 4.5% on the session.
• Analyst outlook: Wall Street is mixed — one Buy, one Hold and one Sell — resulting in an average rating of Hold and a consensus price target of $14.00.
• Fundamentals & ownership: The company reported an EPS beat (‑$1.89 vs. ‑$2.39 estimate) but only $0.44M in revenue and a market cap near $79.8M, with about 59% of shares held by institutions and several major investors increasing positions.

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report)'s share price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $9.70 and traded as low as $8.27. Seres Therapeutics shares last traded at $8.32, with a volume of 52,149 shares changing hands.

Wall Street Analyst Weigh In

MCRB has been the subject of several recent research reports. Wall Street Zen cut Seres Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, February 14th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $22.00 price target on shares of Seres Therapeutics in a report on Friday, March 13th. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Seres Therapeutics in a report on Friday, March 27th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Seres Therapeutics has an average rating of "Hold" and a consensus target price of $14.00.

Seres Therapeutics Trading Down 4.5%

The firm has a fifty day simple moving average of $9.70 and a 200 day simple moving average of $14.49. The stock has a market cap of $79.76 million, a price-to-earnings ratio of 12.61 and a beta of 0.26.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last released its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($1.89) earnings per share for the quarter, beating the consensus estimate of ($2.39) by $0.50. The company had revenue of $0.44 million during the quarter. On average, equities analysts expect that Seres Therapeutics, Inc. will post -0.38 earnings per share for the current year.

Institutional Investors Weigh In On Seres Therapeutics

Several large investors have recently modified their holdings of MCRB. Invesco Ltd. grew its stake in shares of Seres Therapeutics by 193.2% in the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock valued at $96,000 after purchasing an additional 89,995 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Seres Therapeutics by 40.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 21,679 shares during the period. Marshall Wace LLP bought a new stake in shares of Seres Therapeutics in the 2nd quarter valued at approximately $1,016,000. Vontobel Holding Ltd. grew its stake in shares of Seres Therapeutics by 22.6% in the 3rd quarter. Vontobel Holding Ltd. now owns 98,511 shares of the biotechnology company's stock valued at $1,895,000 after purchasing an additional 18,186 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Seres Therapeutics by 6.8% in the 3rd quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company's stock valued at $6,001,000 after purchasing an additional 19,793 shares during the period. 59.34% of the stock is currently owned by institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company's approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.